US › Healthcare

Citius Oncology, Inc. (CTOR)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.66+5.53%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.7M
Net profit
$-26.6M
Profit YoY
-244.0%
EPS
$-0.27
EPS estimate
$-0.01
Net margin
-1,596.0%

EPS came in at -0.27 against a street estimate of -0.01 — a miss of 2600.0%.

Key statistics

Market cap
$55.1M
Forward P/E
35.6
P/B
1.56
Book value
$0.38
EPS (TTM)
$-0.48
52-week high
$2.25
52-week low
$0.49
50-day MA
$0.69
200-day MA
$1.00
Beta
3.48

Analyst view

Analysts rate Citius Oncology, Inc. a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders
77.51%
Institutions
15.32%

Largest institutional holders

FundStake
Armistice Capital, LLC9.88%
Bank of America Corp4.12%
Vanguard Capital Management, LLC0.58%
Geode Capital Management, LLC0.28%
Vanguard Fiduciary Trust Co0.13%
IFP Advisors, LLC0.12%
BlackRock Inc0.05%
Northern Trust Corp0.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Citius Oncology, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.